NYSE:TDOC

Teladoc Health Competitors

Followed 167 Times

$219.55

-34.98 (-13.74 %)

(As of 02/25/2021 12:00 AM ET)

Add

Compare

Today's Range

$216.81

Now: $219.55▼

$246.66

50-Day Range

$220.86

MA: $262.86▼

$294.54

52-Week Range

$102.01

Now: $219.55▼

$308.00

Volume9.02 million shs

Average Volume3.29 million shs

Market Capitalization$31.83 billion

P/E RatioN/A

Dividend YieldN/A

Beta0.3

Teladoc Health (NYSE:TDOC) Vs. SNY, SYK, ISRG, GSK, GILD, and ZTS

Should you be buying TDOC stock or one of its competitors? Companies in the sector of "medical" are considered alternatives and competitors to Teladoc Health, including Sanofi (SNY), Stryker (SYK), Intuitive Surgical (ISRG), GlaxoSmithKline (GSK), Gilead Sciences (GILD), and Zoetis (ZTS).

Teladoc Health vs. Sanofi Stock

Sanofi (NASDAQ:SNY) and Teladoc Health (NYSE:TDOC) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, earnings, analyst recommendations, valuation and profitability.

Earnings & Valuation

This table compares Sanofi and Teladoc Health's revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanofi	$40.00 billion	2.87	$3.26 billion	$3.32	13.80
Teladoc Health	$553.31 million	57.52	$-98,860,000.00	($1.49)	-147.35

Sanofi has higher revenue and earnings than Teladoc Health. Teladoc Health is trading at a lower price-to-earnings ratio than Sanofi, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

6.9% of Sanofi shares are owned by institutional investors. Comparatively, 51.8% of Teladoc Health shares are owned by institutional investors. 1.0% of Sanofi shares are owned by insiders. Comparatively, 3.4% of Teladoc Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Sanofi and Teladoc Health, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanofi	1	4	4	0	2.33
Teladoc Health	0	13	17	0	2.57

Teladoc Health has a consensus price target of $242.5484, indicating a potential upside of 10.48%. Given Teladoc Health's stronger consensus rating and higher possible upside, analysts plainly believe Teladoc Health is more favorable than Sanofi.

Volatility and Risk

Sanofi has a beta of 0.55, indicating that its share price is 45% less volatile than the S&P 500. Comparatively, Teladoc Health has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500.

Profitability

This table compares Sanofi and Teladoc Health's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sanofi	14.49%	24.77%	13.28%
Teladoc Health	-12.71%	-6.15%	-3.75%

Summary

Sanofi beats Teladoc Health on 8 of the 14 factors compared between the two stocks.

Teladoc Health vs. Stryker Stock

Stryker (NYSE:SYK) and Teladoc Health (NYSE:TDOC) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, earnings, analyst recommendations, valuation and profitability.

Earnings & Valuation

This table compares Stryker and Teladoc Health's revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stryker	$14.88 billion	6.21	$2.08 billion	$8.26	29.76
Teladoc Health	$553.31 million	57.52	$-98,860,000.00	($1.49)	-147.35

Stryker has higher revenue and earnings than Teladoc Health. Teladoc Health is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

71.5% of Stryker shares are owned by institutional investors. Comparatively, 51.8% of Teladoc Health shares are owned by institutional investors. 6.8% of Stryker shares are owned by insiders. Comparatively, 3.4% of Teladoc Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Stryker and Teladoc Health, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stryker	2	6	14	1	2.61
Teladoc Health	0	13	17	0	2.57

Stryker currently has a consensus price target of $231.00, indicating a potential downside of 6.01%. Teladoc Health has a consensus price target of $242.5484, indicating a potential upside of 10.48%. Given Teladoc Health's higher possible upside, analysts plainly believe Teladoc Health is more favorable than Stryker.

Volatility and Risk

Stryker has a beta of 0.87, indicating that its share price is 13% less volatile than the S&P 500. Comparatively, Teladoc Health has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500.

Profitability

This table compares Stryker and Teladoc Health's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Stryker	12.35%	20.94%	8.77%
Teladoc Health	-12.71%	-6.15%	-3.75%

Summary

Stryker beats Teladoc Health on 12 of the 15 factors compared between the two stocks.

Teladoc Health vs. Intuitive Surgical Stock

Intuitive Surgical (NASDAQ:ISRG) and Teladoc Health (NYSE:TDOC) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, earnings, analyst recommendations, valuation and profitability.

Earnings & Valuation

This table compares Intuitive Surgical and Teladoc Health's revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intuitive Surgical	$4.48 billion	19.50	$1.38 billion	$9.95	74.55
Teladoc Health	$553.31 million	57.52	$-98,860,000.00	($1.49)	-147.35

Intuitive Surgical has higher revenue and earnings than Teladoc Health. Teladoc Health is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

86.5% of Intuitive Surgical shares are owned by institutional investors. Comparatively, 51.8% of Teladoc Health shares are owned by institutional investors. 1.6% of Intuitive Surgical shares are owned by insiders. Comparatively, 3.4% of Teladoc Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Intuitive Surgical and Teladoc Health, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intuitive Surgical	3	8	10	0	2.33
Teladoc Health	0	13	17	0	2.57

Intuitive Surgical currently has a consensus price target of $736.75, indicating a potential downside of 0.68%. Teladoc Health has a consensus price target of $242.5484, indicating a potential upside of 10.48%. Given Teladoc Health's stronger consensus rating and higher possible upside, analysts plainly believe Teladoc Health is more favorable than Intuitive Surgical.

Volatility and Risk

Intuitive Surgical has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500. Comparatively, Teladoc Health has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500.

Profitability

This table compares Intuitive Surgical and Teladoc Health's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Intuitive Surgical	24.45%	12.08%	10.44%
Teladoc Health	-12.71%	-6.15%	-3.75%

Summary

Intuitive Surgical beats Teladoc Health on 9 of the 14 factors compared between the two stocks.

Teladoc Health vs. GlaxoSmithKline Stock

GlaxoSmithKline (NYSE:GSK) and Teladoc Health (NYSE:TDOC) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, earnings, analyst recommendations, valuation and profitability.

Analyst Ratings

This is a summary of recent ratings and recommmendations for GlaxoSmithKline and Teladoc Health, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GlaxoSmithKline	3	3	6	0	2.25
Teladoc Health	0	13	17	0	2.57

Profitability

This table compares GlaxoSmithKline and Teladoc Health's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
GlaxoSmithKline	18.50%	29.60%	7.11%
Teladoc Health	-12.71%	-6.15%	-3.75%

Institutional and Insider Ownership

11.8% of GlaxoSmithKline shares are owned by institutional investors. Comparatively, 51.8% of Teladoc Health shares are owned by institutional investors. 10.0% of GlaxoSmithKline shares are owned by insiders. Comparatively, 3.4% of Teladoc Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares GlaxoSmithKline and Teladoc Health's revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GlaxoSmithKline	$43.10 billion	2.00	$5.93 billion	$3.17	10.85
Teladoc Health	$553.31 million	57.52	$-98,860,000.00	($1.49)	-147.35

GlaxoSmithKline has higher revenue and earnings than Teladoc Health. Teladoc Health is trading at a lower price-to-earnings ratio than GlaxoSmithKline, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

GlaxoSmithKline has a beta of 0.67, indicating that its share price is 33% less volatile than the S&P 500. Comparatively, Teladoc Health has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500.

Summary

GlaxoSmithKline beats Teladoc Health on 9 of the 14 factors compared between the two stocks.

Teladoc Health vs. Gilead Sciences Stock

Teladoc Health (NYSE:TDOC) and Gilead Sciences (NASDAQ:GILD) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations and dividends.

Analyst Recommendations

This is a breakdown of recent ratings for Teladoc Health and Gilead Sciences, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Teladoc Health	0	13	17	0	2.57
Gilead Sciences	2	12	12	0	2.38

Teladoc Health currently has a consensus target price of $242.5484, indicating a potential upside of 10.48%. Gilead Sciences has a consensus target price of $96.0370, indicating a potential upside of 52.95%. Given Gilead Sciences' higher probable upside, analysts clearly believe Gilead Sciences is more favorable than Teladoc Health.

Profitability

This table compares Teladoc Health and Gilead Sciences' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Teladoc Health	-12.71%	-6.15%	-3.75%
Gilead Sciences	5.48%	37.77%	12.76%

Institutional and Insider Ownership

51.8% of Teladoc Health shares are owned by institutional investors. Comparatively, 76.4% of Gilead Sciences shares are owned by institutional investors. 3.4% of Teladoc Health shares are owned by company insiders. Comparatively, 0.1% of Gilead Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Teladoc Health and Gilead Sciences' top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Teladoc Health	$553.31 million	57.52	$-98,860,000.00	($1.49)	-147.35
Gilead Sciences	$22.45 billion	3.51	$5.39 billion	$6.14	10.23

Gilead Sciences has higher revenue and earnings than Teladoc Health. Teladoc Health is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Teladoc Health has a beta of 0.3, suggesting that its stock price is 70% less volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.51, suggesting that its stock price is 49% less volatile than the S&P 500.

Summary

Gilead Sciences beats Teladoc Health on 10 of the 14 factors compared between the two stocks.

Teladoc Health vs. Zoetis Stock

Teladoc Health (NYSE:TDOC) and Zoetis (NYSE:ZTS) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations and dividends.

Analyst Recommendations

This is a breakdown of recent ratings for Teladoc Health and Zoetis, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Teladoc Health	0	13	17	0	2.57
Zoetis	0	7	8	0	2.53

Teladoc Health currently has a consensus target price of $242.5484, indicating a potential upside of 10.48%. Zoetis has a consensus target price of $167.25, indicating a potential upside of 6.88%. Given Teladoc Health's stronger consensus rating and higher probable upside, analysts clearly believe Teladoc Health is more favorable than Zoetis.

Profitability

This table compares Teladoc Health and Zoetis' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Teladoc Health	-12.71%	-6.15%	-3.75%
Zoetis	25.50%	63.89%	14.99%

Institutional and Insider Ownership

51.8% of Teladoc Health shares are owned by institutional investors. Comparatively, 92.5% of Zoetis shares are owned by institutional investors. 3.4% of Teladoc Health shares are owned by company insiders. Comparatively, 0.2% of Zoetis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Teladoc Health and Zoetis' top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Teladoc Health	$553.31 million	57.52	$-98,860,000.00	($1.49)	-147.35
Zoetis	$6.26 billion	11.88	$1.50 billion	$3.64	42.99

Zoetis has higher revenue and earnings than Teladoc Health. Teladoc Health is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Teladoc Health has a beta of 0.3, suggesting that its stock price is 70% less volatile than the S&P 500. Comparatively, Zoetis has a beta of 0.71, suggesting that its stock price is 29% less volatile than the S&P 500.

Summary

Zoetis beats Teladoc Health on 9 of the 14 factors compared between the two stocks.